Gabelli Funds Cut Gilead Sciences Com (GILD) Holding By $700,000; Bioline RX Ltd (BLRX) Covered By 6 Bullish Analysts Last Week

November 14, 2017 - By Vivian Park

Gabelli Funds Llc decreased Gilead Sciences Inc Com (GILD) stake by 11.56% reported in 2017Q2 SEC filing. Gabelli Funds Llc sold 10,000 shares as Gilead Sciences Inc Com (GILD)’s stock declined 8.05%. The Gabelli Funds Llc holds 76,500 shares with $5.42 million value, down from 86,500 last quarter. Gilead Sciences Inc Com now has $95.14B valuation. The stock declined 0.32% or $0.23 reaching $72.62 per share. About 1,844 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since November 14, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx had 17 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating by TH Capital given on Monday, July 27. Oppenheimer maintained the stock with “Buy” rating in Tuesday, September 12 report. H.C. Wainwright maintained it with “Buy” rating and $4.0 target in Wednesday, October 18 report. As per Wednesday, August 9, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by Oppenheimer given on Tuesday, September 26. The stock has “Buy” rating by Maxim Group on Monday, July 10. The firm earned “Buy” rating on Thursday, May 18 by Maxim Group. As per Thursday, August 3, the company rating was initiated by Roth Capital. The firm earned “Buy” rating on Tuesday, August 8 by Maxim Group. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. See Bioline RX Ltd (NASDAQ:BLRX) latest ratings:

18/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
26/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
26/09/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0 Maintain
12/09/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0 Maintain
08/08/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0000 Maintain
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
08/08/2017 Broker: Maxim Group Rating: Buy New Target: $3.0000 Maintain
04/08/2017 Broker: Oppenheimer Rating: Outperform New Target: $3 Initiates Coverage On
03/08/2017 Broker: Roth Capital Rating: Buy New Target: $3.0000 Initiate
10/07/2017 Broker: Maxim Group Rating: Buy New Target: $3.0000 Maintain

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 EPS, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.19 billion for 10.87 P/E if the $1.67 EPS becomes a reality. After $2.23 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 12 Hold. Therefore 60% are positive. Gilead Sciences had 106 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Thursday, September 28 with “Buy”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Tuesday, March 15 by Jefferies. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Tuesday, September 6 by Jefferies. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by Needham on Tuesday, October 3. The rating was maintained by RBC Capital Markets on Monday, October 3 with “Outperform”. William Blair maintained the shares of GILD in report on Wednesday, June 14 with “Buy” rating. As per Friday, December 4, the company rating was maintained by Wells Fargo. Jefferies maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, October 4. Jefferies has “Hold” rating and $93 target. The firm earned “Hold” rating on Tuesday, May 30 by Maxim Group. The firm has “Outperform” rating given on Tuesday, October 20 by Oppenheimer.

Since June 1, 2017, it had 0 buys, and 2 sales for $5.11 million activity. MARTIN JOHN C also sold $4.78M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, June 1. Alton Gregg H also sold $325,114 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, June 1.

Investors sentiment increased to 0.93 in Q2 2017. Its up 0.02, from 0.91 in 2017Q1. It improved, as 78 investors sold GILD shares while 538 reduced holdings. 110 funds opened positions while 462 raised stakes. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. 17.05M were accumulated by Invesco Limited. Ls Invest Advsr Ltd Co invested 0.61% in Gilead Sciences, Inc. (NASDAQ:GILD). Kentucky Retirement Sys invested in 83,767 shares or 0.45% of the stock. South Street Advsr Llc reported 13,730 shares. Private Na has 4,611 shares. Cornercap Inv Counsel Incorporated holds 0.66% or 55,395 shares. Caprock stated it has 4,539 shares or 0.07% of all its holdings. Segall Bryant & Hamill Ltd stated it has 75,592 shares or 0.13% of all its holdings. Welch Forbes Ltd owns 164,114 shares. Bp Public Ltd Company reported 151,000 shares. Exane Derivatives owns 15,962 shares. Moreover, Investment House Limited Liability Co has 0.77% invested in Gilead Sciences, Inc. (NASDAQ:GILD). 938,419 are owned by Cincinnati. Neville Rodie Shaw has invested 0.34% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Wg Shaheen And Associate Dba Whitney And stated it has 39,465 shares or 0.92% of all its holdings.

Gabelli Funds Llc increased Stericycle Inc Com (NASDAQ:SRCL) stake by 65,000 shares to 88,000 valued at $6.72 million in 2017Q2. It also upped Deutsche Bank Ag (NYSE:DB) stake by 23,500 shares and now owns 69,500 shares. Chevron Corp (NYSE:CVX) was raised too.

It closed at $1.01 lastly. It is down 6.10% since November 14, 2016 and is downtrending. It has underperformed by 22.80% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com